Mydecine reports a net loss of CAD$5.2 million for Q1 2021, with cash and cash equivalents of CAD$11.3 million at the end of the quarter.
Articles
Politicians And Regulators Require Re-Education On Drugs
The Psychedelic Drug Revolution has begun. Standing in the way are politicians and regulators, saddled with archaic anti-drug phobias. They need to be educated.
Novamind Opens Client Care Center to Support High Demand for Treatments
Novamind is adding a second Client Care Center as it expands its clinic network from four to eight locations.
More than 80% of Americans report one or more symptoms of depression, and many have turned to substances to cope with negative emotions during COVID-19 Pandemic, according to Field Trip Health’s First Annual “State of Mind” Survey
Over 80% of Americans are exhibiting symptoms of depression related to the COVID-19 pandemic. Nearly 1 in 4 Americans have experienced suicidal or self-destructive thoughts.
Canadians Are Not OK, 83% of Canadians Report One Or More Symptoms of Depression With Many Turning To Substances To Cope With Negative Emotions During COVID-19 Pandemic, According to Field Trip Health's First Annual "State of Mind" Survey
Over 80% of Canadians are showing symptoms of depression related to the COVID-19 pandemic, with over half of Canadians feeling "down, depressed or hopeless".
Alabama Governor Signs Medical Marijuana Legalization Bill
The governor of Alabama on Monday signed a bill to legalize medical marijuana in the state that was sent to her desk earlier this month.
FDA Endorses Psychedelics 'Guided Experience' Model
The FDA has approved the use of MDMA by therapists -- to better prepare them to administer MDMA-assisted psychotherapy.
Decriminalizing Psychedelic Drugs in California: As State Senate Considers Bill, Debate Continues
A bill to decriminalize psychedelic drugs is currently being considered by the California Legislature.
MindMed Announces 2021 Q1 Financial Results; Cash Balance of $160m USD ($194m CAD) to Execute on Diverse Clinical Pipeline
MindMed reports a net loss of CAD$14 million for Q1, with US$160 million in cash and a total cash burn for the quarter of CAD$10 million.
Psychedelic Drugs To The Rescue: Professional Sports Turn To Psychedelics
Traumatic Brain Injury is another major treatment market targeted by psychedelics R&D. TBIs are now a health crisis in many professional sports. Opportunity knocks.
Turn On, Tune In, Feel Better: The Rise of Psychedelic Therapy in Texas
On the day it opened in early May, Field Trip Health’s therapeutic facility in Houston’s uptown neighborhood looked a little like a high-end strip-mall spa. Dressed in a floral shirt, Matt Emmer, the company’s director of operations and business development, showed me the clinic’s amenities.
Some people with color blindness report improved color vision after psychedelic drug use
A new report published in Drug Science, Policy and Law suggests that psychedelic drugs may improve symptoms of color blindness.
Numinus Wellness Announces Key Leadership Hires to Support Rapid Growth and Innovation
Numinus fills several key roles including a new Director of Mergers and Acquisitions and a new Chief Communications Officer.
Media Coverage Of Psychedelic Drugs Soars
For a solid month, there has been an explosion in coverage of the psychedelic drug industry by the mainstream media.
COMPASS Pathways plc announces financial results and business highlights for the first quarter 2021
Compass Pathways highlights for Q1 include two new patents and reports its Phase IIb clinical trial is on track.